The biotech is entering a new era.
Zacks Investment Research on MSN
Is cancer the turnaround Moderna has been looking for post-COVID?
Shares of Moderna MRNA have staged a remarkable comeback this year as investors increasingly warm to the possibility that the company can rebuild its business beyond COVID-19 vaccines. After becoming ...
But what has the stock done for shareholders lately? How has it done over the past five years? Not so great. It has averaged ...
Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be.
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and ...
President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma support a broader effort ...
mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved product Company expects supply to be available ... · ACCESS Newswire · Moderna, Inc. The above button links to ...
Even with a modest 25% success rate for the company's current phase 2 programs, Moderna should be able to launch enough new ...
Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized ...
A former Senior Publishing Editor on the Dow Jones Newswires team at The Wall Street Journal, Aaron earned a Bachelor's degree in Economics from the University of Michigan and a Master's in Journalism ...
After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of ...
After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the biotech company a much-needed win.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results